Ultrasound-Mediated Drug Delivery With a Clinical Ultrasound System: In Vitro Evaluation

Josanne S. de Maar¹, Charis Rousou², Benjamin van Elburg³, Hendrik J. Vos⁴, Guillaume P.R. Lajoinie⁵, Clemens Bos¹, Chrit T.W. Moonen¹ and Roel Deckers¹*

¹Imaging and Oncology Division, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, ²Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands, ³Physics of Fluids Group, MIRA Institute of Biomedical Technology and Technical Medicine, University of Twente, Enschede, Netherlands, ⁴Laboratory of Acoustical Wavefield Imaging, Faculty of Applied Sciences, Delft University of Technology, Delft, Netherlands

Chemotherapy efficacy is often reduced by insufficient drug uptake in tumor cells. The combination of ultrasound and microbubbles (USMB) has been shown to improve drug delivery and to enhance the efficacy of several drugs in vitro and in vivo, through effects collectively known as sonopermeation. However, clinical translation of USMB therapy is hampered by the large variety of (non-clinical) US set-ups and US parameters that are used in these studies, which are not easily translated to clinical practice. In order to facilitate clinical translation, the aim of this study was to prove that USMB therapy using a clinical ultrasound system (Philips iU22) in combination with clinically approved microbubbles (SonoVue) leads to efficient in vitro sonopermeation. To this end, we measured the efficacy of USMB therapy for different US probes (S5-1, C5-1 and C9-4) and US parameters in FaDu cells. The US probe with the lowest central frequency (i.e. 1.6 MHz for S5-1) showed the highest USMB-induced intracellular uptake of the fluorescent dye SYTOX™ Green (SG). These SG uptake levels were comparable to or even higher than those obtained with a custom-built US system with optimized US parameters. Moreover, USMB therapy with both the clinical and the custom-built US system increased the cytotoxicity of the hydrophilic drug bleomycin. Our results demonstrate that a clinical US system can be used to perform USMB therapy as efficiently as a single-element transducer set-up with optimized US parameters. Therefore, future trials could be based on these clinical US systems, including validated US parameters, in order to accelerate successful translation of USMB therapy.

Keywords: USMB, sonoporation, sonopermeation, ultrasound, microbubbles, chemotherapy, drug delivery, imaging

INTRODUCTION

Chemotherapy is typically used as systemic treatment to destroy metastatic cancer cells that have spread away from the primary tumor. However, local action of chemotherapy is also of importance throughout the spectrum of oncological therapy. First, surgically unresectable tumors can be made operable with neoadjuvant chemotherapy (Sclafani et al., 2017; Fietkau et al., 2021). Secondly, neoadjuvant chemotherapy can lead to less extensive surgery and reduce the risk of local recurrences (Dietz et al., 2018; van Ramshorst et al., 2018). Third, chemotherapy can enhance the local effect of...
delivery of such drugs may be beneficial (Chong et al., 2018; Frinking et al., 2020). Unfortunately, there is substantial heterogeneity in the local response to systemic treatment within and across cancer types. A plausible explanation for suboptimal response is the heterogeneous and/or insufficient delivery of drugs to tumor cells caused by biophysical barriers of the tumor tissue (Tredan et al., 2007; de Maar et al., 2020).

The combination of ultrasound and microbubbles (USMB) has been shown to overcome these biophysical barriers and increase local tumor uptake of several drugs resulting in enhanced efficacy (Lammertink et al., 2015b; Snipstad et al., 2018; Kooiman et al., 2020). Microbubbles are micron sized (1–10 µm in diameter) gas-filled particles with a biocompatible shell that are widely used as vascular contrast agents for ultrasound imaging (Chong et al., 2018; Frinking et al., 2020). In addition, the interaction of US waves and microbubbles has the potential to enhance the delivery of drugs. Microbubbles exposed to low-intensity US fields will oscillate (i.e., stable cavitation), while microbubbles exposed to higher intensities will collapse violently (i.e., inertial cavitation). Both types of cavitation lead to a number of bio-effects collectively known as sonоперmeation, such as the formation of pores in cell membranes (sonoporation), enhanced endocytosis and increased vascular permeability, that improve the deposition of drugs in tumor tissue (Snipstad et al., 2018; Deprez et al., 2021).

In particular, hydrophilic drugs such as bleomycin and cisplatin, that have difficulties crossing the cell membrane, may benefit from local USMB therapy, leading to increased delivery of such drugs in vitro (Iwanaga et al., 2007; Watanabe et al., 2008; Maeda et al., 2009; Heath et al., 2012; Sasaki et al., 2012; Lamanaukas et al., 2013; Sato et al., 2014; Sato et al., 2015; Lammertink et al., 2016; Tamosiunas et al., 2016; Hirabayashi et al., 2017; Sasaki et al., 2017; Chen et al., 2018; Fekri et al., 2019) and increased anti-tumor response in vivo (Iwanaga et al., 2007; Watanabe et al., 2008; Heath et al., 2012; Sato et al., 2014; Sato et al., 2015; Hirabayashi et al., 2017; Chen et al., 2018). The first clinical trials using the combination of chemotherapy and USMB have been conducted. In a phase 1 clinical trial, USMB with clinically available microbubble SonoVue was combined with gemcitabine in ten inoperable pancreatic cancer patients. Trial participants could tolerate significantly more treatment cycles and the median overall survival was longer compared to historical controls treated with gemcitabine alone (Kotopoulos et al., 2013; Dimecavski et al., 2016). Another phase 1 trial in eleven patients with hepatic metastases and one patient with pancreatic cancer concluded that treatment with physician’s choice chemotherapy (most commonly FOLFIRI, i.e., folinic acid, fluorouracil and irinotecan) plus USMB with SonoVue was safe (Wang et al., 2018). Several follow-up phase 1/2 studies are currently recruiting or being prepared (Clinicaltrials.gov NCT04146441, NCT04821284, NCT03477019 and NCT03458975). A phase 3 trial investigates the addition of USMB to neoadjuvant chemotherapy in breast cancer (Clinicaltrials.gov NCT03385200, current status unknown).

Despite these promising developments, translation of USMB therapy from in vitro and small animal studies to the clinic is still limited. One major obstacle for clinical translation of USMB therapy is the lack of a clinically approved US system with settings optimized to perform USMB therapy. A large variety of (non-clinical) US set-ups and US parameters have been used for in vitro and in vivo studies (Roovers et al., 2019). While these studies have provided invaluable insights on the underlying mechanisms of USMB therapy and provided in vivo proof of concept, their methods and results cannot be easily transferred to clinical studies because the US equipment is not, and will not likely be, approved for clinical use. In this study we take a different approach to facilitate the clinical translation of USMB therapy by investigating the potential of an existing clinical ultrasound system (Philips iU22) in combination with clinically available microbubbles (SonoVue) to perform USMB therapy. To this end, we use in vitro experiments to evaluate the effect of USMB therapy on the intracellular uptake of a model drug (SYTOX™ Green) and the efficacy of the hydrophilic chemotherapeutic drug bleomycin.

**MATERIALS AND METHODS**

**Chemicals and Reagents**

All cells were cultured in high glucose Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% non-essential amino acids (NEAA).

Dulbecco’s Phosphate Buffered Saline (PBS), modified, without calcium, chloride and magnesium chloride was used as solvent and for washing steps.

PBS, DMEM, FBS, NEAA and trypsin/ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma-Aldrich (St. Louis, United States).

Bleomycin sulfate (Bleomendac® powder for solution for injection, GmBH, Wedel, Germany) was dissolved in sterile 0.9% NaCl to reach a final concentration of 10 µg/ml, which corresponds to at least 15IU (Ph. Eur) per ml. Bleomycin is hydrophilic (LogP-7.5) and has a molecular weight of 1,415.6 g/mol.

SYTOX™ Green is a cell-impermeant fluorescent nuclear acid stain with excitation/emission wavelength of 504/523 nm. Its impermeability and >500-fold fluorescence enhancement after binding to nuclear acids makes it suitable to visualize USMB therapy efficacy. DRAQ5™ fluorescent probe is a cell-permeant fluorescent dye (excitation 647 nm, emission 681 nm) that was used to counterstain the DNA content of all cells. AlamarBlue™ reagent was used for the cell viability assay. The eBioscience™ Annexin V Apoptosis Detection Kit APC, containing both fluorescently labelled Annexin V and Propidium Iodide (PI), was used for the apoptosis assay. SYTOX™ Green, DRAQ5™, AlamarBlue™ and eBioscience™ Annexin V Apoptosis Detection Kit APC were purchased from [1](https://pubchem.ncbi.nlm.nih.gov/compound/Bleomycin#section=CAS [Accessed August 31st, 2021]).
ThermoFisher Scientific (Waltham, Massachusetts, United States).

**Cell Culture**

A human pharyngeal squamous cell carcinoma cell-line (FaDu) (ATCC® HTB-43™, LGC Standards GmbH, Wedel, Germany) was cultured in high glucose DMEM supplemented with 10% FBS and 1% NEAA. FaDu cells were cultured in a humidified incubator at 37°C and 5% CO2. They were split 2–3 times per week at a confluency of around 80%, until a maximum passage number of 20. One day before each experiment, FaDu cells collected using trypsin/EDTA and seeded in a 35 mm diameter lumox® culture dish (Sarstedt AG & Co. KG, Nümbrecht, Germany).

**Ultrasound Systems and Microbubbles**

SonoVue (Bracco International B.V., Amsterdam, Netherlands) was prepared according to the manufacturer’s instructions, producing sulfurhexafluoride-filled phospholipid microbubbles with a mean bubble diameter of ~2.5 µm and a concentration of 1–5*10^7 microbubbles/ml in sterile 0.9% NaCl. Microbubbles were kept at 4°C in between use, resuspended before every use and used within 2 h after preparation.

We used a clinical ultrasound system (iU22 ultrasound system, Philips Medical Systems Nederland B.V., Best, Netherlands) combined with the following probes: S5-1, C5-1 and C9-4. USMB therapy was done in Pulsed Wave (PW) Doppler mode. The transmission frequency of each transducer was set by the system and cannot be changed. The Pulse Repetition Period (PRP) was set to the longest period for each transducer by setting the scale parameter to the minimum. The Pulse Repetition Frequency (PRF) was set to 6.7 kHz, for all frequencies used throughout the rest of the paper, namely 1.6, 2.25 and 4 MHz. All measurements were performed with diluted (1,000x) SonoVue and without microbubbles for reference.

Attenuation coefficients were calculated by comparing the transmission through the SonoVue solution to that through distilled water:

\[
\alpha = -10 \log_{10} \left( \frac{|V_S(f_i)|^2}{|V_R(f_i)|^2} \right),
\]

where \(\alpha\) is the attenuation coefficient in dB/cm, \(d\) is the acoustical path length through the sample in cm, \(|V_S(f_i)|\) and \(|V_R(f_i)|\) are the amplitudes of the frequency spectra of the SonoVue and reference signal, respectively, at the transmit frequency \(f_i\).

**USMB Therapy Experimental Set-Up**

In order to apply USMB therapy to cells cultured in lumox® dishes we used TwentiCells, which were designed and manufactured at Twente University (Figure 1). The TwentiCell consists of a 3D-printed lumox® dish holder and a screw-on ring to seal the lumox® dish with a polyolefin (25 µm thick), creating a water-tight compartment. The holder contains an inlet and outlet to let the compartment with drugs/microbubbles in solution and remove unwanted air, respectively. The parts were assembled before each experiment and UV-sterilized before inserting the lumox® dish containing the cells to avoid infection. Acoustic transparency of the TwentiCells and inserted lumox® dishes is close to 100% (data not shown).

For the USMB therapy the TwentiCell was immersed in degassed water (T = 37°C) and fixed above the transducer in a custom-built frame. The distance between the surface of the clinical ultrasound probes and the lumox® dish membrane was 3.0 cm and the PW Doppler Sample Volume was centered on this position (Figure 1C). In the single-element transducer set-up the lumox® dish membrane was positioned in the focal zone of the transducer, i.e. 8.0 cm above the transducer surface (Figure 1D).

**SYTOX™ Green Experiments**

One day after seeding 3.0 × 10⁶ FaDu cells in lumox® dishes, the medium was removed and a mixture of 2 µl SYTOX™
Green (SG, 5 mM solution in DMSO), 180 µl SonoVue and 4.8 ml medium was added to the TwentiCell. For USMB-untreated samples, a lumox® dish with regular lid was used and the volumes were adjusted to 0.5 µl SG, 45 µl 0.9% NaCl and 1.2 ml medium. The TwentiCells were incubated (37°C and 5% CO2) for 15 min with the cell containing surface upwards, in order for the microbubbles to float towards the cells. Next, the TwentiCell was placed in the waterbath (cell containing surface remaining upwards), exposed to ultrasound for 15 s and put back in the incubator. The US-untreated samples were not removed from the incubator. 30 min after USMB treatment, the SG-containing medium was removed and clean medium was added. Afterwards, the cells were washed with PBS, fixated with paraformaldehyde (4% in PBS) and stained with 1 ml DRAQ5 (5 µM in PBS) at 37°C for about 20 min. The lumox® membrane was covered with solidifying mounting medium FluorSave™ (Merck Millipore, Burlington, Massachusetts, United States) and a glass cover slip, and kept in the dark at 4°C until fluorescence imaging. These experiments were performed with the single element transducer as well as the clinical US system.

**Bleomycin Experiments**

One day after seeding 1.5 × 10⁵ FaDu cells in lumox® dishes, the medium was removed and a mixture of 498 µl bleomycin solution or 0.9% NaCl, 180 µl SonoVue and 4.302 ml medium was added to the TwentiCell. For US-untreated samples, a lumox® dish with regular lid was used and the volumes were adjusted to 125 µl bleomycin solution or 0.9% NaCl, 45 µL 0.9% NaCl and 1.075 ml medium. The TwentiCells were incubated (37°C and 5% CO2) for 15 min with the cell containing surface upwards. Next, the TwentiCell was placed in the waterbath (cell containing surface remaining upwards), exposed to ultrasound for 15 s and put back in the incubator. The US-untreated samples were not removed from the incubator.

To determine the IC₅₀ and IC₂₅ of bleomycin with or without USMB, the final bleomycin concentrations were 0, 0.1, 0.5, 1, 5, 10, 50, 100 and 500 µg/ml and the single-element transducer setup was used. The apoptosis assay was performed at a single bleomycin concentration (10 µg/ml) using the single-element setup as well as the clinical US system.

Two hours after USMB therapy, the bleomycin or 0.9% NaCl containing medium was removed, the cells were washed with PBS
and clean medium was added. The cells were then incubated at 37°C, 5% CO₂ until 48 h after adding the bleomycin, microbubbles and/or 0.9% NaCl.

** Fluorescence Microscopy **

Fluorescence imaging for the SG experiments was performed on a Confocal Zeiss LSM 700 microscope. SG was imaged with excitation 488 nm and emission > 500 nm. DRAQ5 was imaged with excitation 639 nm and emission > 640 nm. All microscope settings, including laser power, gain, pinhole size and digital offset, were kept constant during all experiments. Images were obtained with 10 times enlargement with a frame size of 512 × 512 and a square tile size of 640.17 µm². For each lumox® dish, a square of 10 by 10 tiles was imaged with a 10% overlap, starting in the visual center of the SG signal. The tiles were stitched immediately after acquisition. In each tile a Z-stack of three levels was created to compensate for height variances of the cells over the tiles.

To quantify the USMB efficacy for different US-settings we performed automated cell segmentation of SG-positive and DRAQ5-positive cells using (Fiji Is Just) ImageJ 2.0.0-rc-69. First, a standard-deviation Z-projection was created for the SG and DRAQ5 images. To segment the SG-positive cells global thresholding was applied, with a fixed threshold for all samples, whereas for segmenting the DRAQ5-positive cells a local threshold was applied (i.e., mean method with a radius of 5). Next, the noise in the binary masks after thresholding was removed with a median filter and the watershed algorithm was applied to split clustered objects. Objects with a size >20 pixel units were counted as cells, regardless of circularity.

The number of SG and DRAQ5-positive cells were analyzed in a region of interest (ROI) of 600 × 600 pixels, centered on the position with the highest SG signal after blurring the SG image with a 2-D Gaussian smoothing kernel with standard deviation of 200 in Matlab (R2019a). When there was no noteworthy SG signal, the ROI was positioned in center of the 10 × 10 square. Objects on the edges of the ROI were not counted.

The fluorescence intensity in the well plate was measured using the FLUOstar OPTIMA (BMG LABTECH) plate reader, with excitation and emission wavelengths of 550–10 and 600–610 nm and a gain of 1,500. The cell viability of a sample was calculated as percentage fluorescent signal relative to that of untreated control samples, after subtraction of the fluorescent signal of a negative control without cells.

To determine IC₅₀/IC₂₅ in each group (with or without USMB), the cell viability percentages were calculated with reference to their own controls, i.e., no exposure to bleomycin but with or without USMB depending on the group. The IC₅₀ was then defined as the concentration resulting in 50% inhibition of cell viability, likewise, the IC₂₅ was the concentration resulting in 25% inhibition of cell viability. The method to determine IC₅₀/IC₂₅ is described in Statistical Analysis.

** Apoptosis Assay **

In addition to the viability assay, an apoptosis assay was performed to determine the effect of USMB on bleomycin efficacy. The apoptosis and viability assays were performed in separate experiments. 48 h after adding medium with or without bleomycin and with or without microbubbles to the Twenticell, the medium and detached cells were collected from each lumox® dish. The remaining cells were detached from the lumox® membrane with trypsin/EDTA and added to the rest of the medium. Residual EDTA was removed by centrifugation and washing with PBS. The cells were resuspended in binding buffer with a concentration of ~1 × 10⁶ cells/ml and then stained and incubated for 15 min with Annexin V. The cells were washed, resuspended in binding buffer, stained with Propidium Iodide (PI) and then kept on ice protected from light.

Within 4 h, the samples were analyzed by flow cytometry using the BD FACSCanto™ II Cell Analyzer, for PI (488 nm) and Annexin V (633 nm). Compensation was performed with samples stained with only PI and only Annexin V. The FACS data was analyzed using FlowJo 10.7.1. The four quadrants (live, early apoptotic, late apoptotic, and necrotic cells) were distinguished based on a control sample containing 50% necrotic and 50% live cells.

** Statistical Analysis **

Statistical analysis was performed in GraphPad Prism 8.3.0. For the fluorescence microscopy data and cell viability data we used the Kruskal Wallis test and a Dunn’s test for multiple comparisons. The absolute IC₅₀ for bleomycin with and without USMB was determined with a nonlinear least-squares regression of the bleomycin concentration versus the response (cell viability percentage) with the Hill’s slope fixed at ~1.0 and the top and bottom of the fitted curve restrained to 100 and 0%, respectively. To compare the IC₅₀’s of both groups we used the extra sum of squares F-test. Because the IC₅₀’s had a very broad confidence interval we also calculated the IC₂₅ for both groups with the same method. A p-value < 0.05 was considered to indicate a statistically significant difference.

** RESULTS **

**Acoustic Characterization of Clinical US System**

The acoustic output of the clinical ultrasound system as well as the US beam profile were characterized for the probes S5-1, C5-1 and C9-4. The acoustic output as function of different US settings is summarized in Table 1. With increasing SV, the number of cycles per pulse increased. The maximum MI (and therefore pressure) increased with decreasing SV. Figure 2 shows the characteristics of the S5-1 probe. Supplementary Figures S1–S3 show these characteristics for the other clinical US
The attenuation coefficient decreased, mainly at 1.6 MHz, as the excitation pressure was increased from 150 to 750 kPa. This observation is consistent with previous experimental measurements of pressure-dependent attenuation coefficients (Tang and Eckersley, 2007; Emmer et al., 2009). As we have observed no visible trace of bubble destruction based on the repeated pulses, the refreshment rate of the bubble solution appears to be sufficient, and we ascribe this effect to radiation forces and bubble clustering. As such, this effect may be even more prominent at the higher concentrations used for the cell experiments.

When comparing rectangular versus Gaussian envelop shapes, no differences were observed in attenuation coefficient. Furthermore, the number of cycles per pulse did not influence the attenuation coefficient.

### Effect of Transducer and Ultrasound Settings on USMB Efficiency

The USMB efficacy for each transducer as function of acoustic pressure is shown in Figure 4A. The percentage of SG positive cells increased significantly with the addition of USMB treatment using the S5-1 (1.6 MHz) or C5-1 (2.25 MHz) probes and was comparable (C5-1) or even higher (S5-1) than with the single element transducer (Figure 4A). In contrast, no relevant SG uptake was observed using the C9-4 probe (4.0 MHz). For the S5-1 probe and the single element transducer showed a pressure-dependent increase of SG positive cells, reaching ~30 and 15% at the highest pressures, respectively.

The effect of pulse length for the S5-1 and C5-1 is shown in Figure 4B. For the S5-1 probe at maximum pressure (0.59 MPa), a similar percentage of SG positive cells (i.e., 38%) was observed independent of pulse length. For the S5-1 probe at a lower pressure (0.38 MPa) only a higher number of cycles per pulse (SV 20 and 10 mm) caused a significant increase in SG positive cells compared to USMB untreated samples. For the C5-1 probe and the single element transducer showed a pressure-dependent increase of SG positive cells, reaching ~30 and 15% at the highest pressures, respectively.

The absolute IC50 of bleomycin decreased from 263.9 μg/ml (95% CI 32.0–111.0) to 57.73 μg/ml (95% CI 3.74–374.8) to 57.73 μg/ml (95% CI 3.74–374.8) when combined with USMB (Pneg = 0.56 MPa). The USMB-induced difference in IC50 was statistically significant (p < 0.0001). The IC50 decreased significantly from 263.9 μg/ml (95% CI 192.9–374.8) to 57.73 μg/ml (95% CI 32.0–111.0) (p < 0.0001). Note that both curves have their own reference of 100% cell viability without bleomycin (i.e., with or without USMB), which guarantees that the observed differences in IC25 and IC50 are not a direct cytotoxic effect of USMB alone, but due to enhanced intracellular delivery of bleomycin causing more cell
death at the same concentration. The effect of USMB treatment in the absence of bleomycin is illustrated in Figure 5B. Cell viability did not significantly decrease with increasing acoustic pressure.

The apoptosis assay confirmed the decreasing cell viability with addition of USMB to bleomycin. Figure 5C shows the mean distribution of cells over the quadrants after USMB with the single-element transducer. Representative dot plots of flow cytometry analysis from experiments with two or three samples per group are shown in Figure 5D. Increased apoptosis was observed 48 h after bleomycin plus USMB (P_{neg} 0.56 MPa), compared to untreated samples or samples treated with either bleomycin alone or USMB alone.

Effect of USMB With Clinical US System on Bleomycin Efficacy

Figure 6 demonstrates that the cytotoxicity of bleomycin could also be increased by USMB therapy using the clinical US system.
with the S5-1 probe. The combination of bleomycin (10 μg/ml) and USMB with significantly decreased the cell viability compared to untreated samples at the three pressures used, while either bleomycin alone or USMB alone had little effect (Figure 6A). Addition of USMB at $P_{\text{neg}}$ 0.59 MPa (MI 0.6) to bleomycin, also significantly decreased the cell viability from 94 to 47% compared to samples treated with bleomycin alone. At the lower pressures we also observed a decrease in cell viability when USMB was added to bleomycin (from 94 to 57% at $P_{\text{neg}}$ 0.46 MPa and to 54% at $P_{\text{neg}}$ 0.38 MPa), however these changes were not significant.

The results of the apoptosis assay again confirmed the decrease in cell viability with the combination of bleomycin and USMB. Figure 6B shows the mean distribution of cells over the quadrants after USMB with the clinical US system and S5-1 probe. Representative dot plots of flow cytometry analysis from experiments with two or three samples per group are shown in Figure 6C. Besides increased apoptosis, similar to what was seen with the single element transducer, also increased necrosis (11.4 vs. 8% with bleomycin alone) was observed after bleomycin plus USMB with the clinical US system.

**DISCUSSION**

In preclinical studies, USMB therapy has overcome biophysical barriers that cause heterogeneous and/or insufficient drug delivery to tumor cells, thereby increasing intracellular uptake and enhancing the efficacy of several drugs. Although the first clinical studies have been published, clinical translation of USMB therapy is still limited. We hypothesize that clinically available US systems with fixed and validated parameters will accelerate clinical translation. To pave the road forwards, we characterized several clinical probes and US-parameters and showed that effective USMB therapy can be performed *in vitro* with a non-modified clinical US system and EMA/FDA approved microbubbles.

After evaluation of three clinical US probes and a set of parameters, the US probe with the lowest center frequency (i.e., 1.6 MHz for S5-1) showed the highest USMB efficiency as measured by SG uptake. This was consistent with literature showing that a frequency close to the resonance frequency of SonoVue [i.e., 1.6–3.1 MHz depending on the bubble size (van der Meer et al., 2004)] was the most efficient (Kooiman et al., 2014; Roovers et al., 2019). Moreover, at lower pressures a larger
number of cycles per pulse was beneficial. This was also seen in previous studies, although some conflicting results have been reported and intermediate pulse lengths might be optimal (Rahim et al., 2006; Karshafian et al., 2009; Phillips et al., 2010; Keller et al., 2019; Roovers et al., 2019). The SG uptake levels that we achieved with the clinical US system were comparable, or even higher depending on the transducer and US-settings, to those obtained with a custom-built US set-up with a single-element transducer and optimized US parameters (Lammertink et al., 2015a). A possible explanation for these higher uptake levels would be that the gradually increasing pressure in the Gaussian pulse shape of the PW Doppler mode leads to a more efficient bubble response than the block shaped pulse of the single-element transducer. However, we found no evidence in our microbubble attenuation experiments to support this. Since the experimental set-up and handling were equal for both set-ups and the frequencies of S5-1 probe (1.6 MHz) and the transducer of the custom-build set-up (1.5 MHz) were very similar we conclude that the improved USMB efficiency using the S5-1 and C5-1 probes must be due to other factors that we did not investigate (e.g., PRF, non-linear US propagation and beam shape). Future experiments including cavitation measurements might further elude the underlying mechanisms.

In this study we used the PW Doppler mode for USMB therapy, in contrast to previous clinical studies that used B-mode and contrast mode, or color power angiography doppler (Clinicaltrials.gov NCT03385200, personal communication). The first clinical trial used B-mode, with settings optimized to achieve a linear acoustic signal, the maximum possible duty cycle (1%), center frequency of 1.9 MHz and MI 0.4 (measured pressure 0.27 MPa Pneg) (Kotopoulis et al., 2013; Dimcevski et al., 2016). The second clinical trial did not provide details about specific ultrasound settings used, apart from the MI that varied between 0.4 and 1.0 (Wang et al., 2018). Although not clinically applied, PW Doppler on a clinical US system has been evaluated in a mouse study for blood-brain barrier disruption using a variation of clinically available US parameters (e.g., frequency 5.0–8.0 MHz) (Bing

![FIGURE 4](image-url)
et al., 2009). As demonstrated by the pressure fields (Figure 2B and Supplementary Figures S1, S2), PW Doppler mode creates a very small (5.0 mm by 6.3 mm for S5-1) USMB therapy focus, much smaller than the treatment area described in the previous phase 1 clinical trial (i.e., 69 * 100 * 1.0 mm³) (Kotopoulis et al., 2013). Therefore, PW Doppler mode is well suited for precisely targeted treatment. In addition, the use of a clinical US imager provides the opportunity to perform imaging and therapy consecutively, thus performing image-guided therapy.

This is to our best knowledge the first in vitro study that evaluates the effect of USMB therapy using a clinical US system and approved SonoVue microbubbles, while performing extensive evaluation of multiple transducers and US settings available in PW Doppler mode. Previously, in vitro studies have used Optison microbubbles for USMB therapy with clinical US systems in spectral Doppler, 2-D scan mode or harmonic imaging (Octave) mode at a frequency of 1.5 of 3.5 MHz (Miller and Quddus, 2000; Miller et al., 2003). Compared to our findings, these methods resulted in a lower...
USMB efficacy (below 10%), which could indicate that PW Doppler mode is more effective. Other in vitro studies have used a diagnostic US system to evaluate microbubble response, while therapeutic USMB was omitted or administered with a non-clinical transducer (Keravnou et al., 2015; Keller et al., 2019; Keller et al., 2021). USMB therapy would benefit from simultaneous (real-time) cavitation monitoring with a single transducer of a clinical US system. This solution would allow for monitoring of bioeffects (Chen et al., 2003; Hallow et al., 2006; Tamosiunas et al., 2012; Maciulevicius et al., 2015), while using standardized US settings. Currently, simultaneous USMB therapy and cavitation monitoring is not yet available on clinical US systems, although our work and the work by Keller et al. show it is technically feasible (Keller et al., 2021). Meanwhile, our approach leads to a standardization of US parameters used and may be immediately used in clinics.

Next to correct determination and extensive reporting of the US exposure conditions used (ter Haar et al., 2011), which has been performed for clinical US systems, and performing cavitation monitoring during treatment, the use of mono-disperse microbubbles will further reduce the disparity of experimental results. Currently, commercial, clinically approved microbubbles

![Cell viability after bleomycin ± USMB using the clinical US system with S5-1 probe](A) Bleomycin 10 μg/ml or NaCl 0.9% with (red, circles) and without (blue, triangles) USMB at three pressures (MI 0.6, 0.5 and 0.4). Symbols indicate individual measurements and bars indicate mean and SD (n ≥ 3). *p < 0.05 **p < 0.01 (B) Flow cytometry analysis of Propidium Iodide and Annexin V staining 48 h after bleomycin 10 μg/ml or NaCl 0.9% with or without USMB at P_{neg} 0.59 MPa (MI 0.6), pie charts represent the mean of the samples with n = 2 or (for bleomycin + USMB samples) n = 3. (C) Representative dot plots of flow cytometry analysis shown in (B). More apoptosis and necrosis was observed after bleomycin + USMB. Bleo: bleomycin; MI: Mechanical Index; P_{neg}: Peak negative pressure; USMB: ultrasound and microbubbles.

**FIGURE 6** Cell viability after bleomycin ± USMB using the clinical US system with S5-1 probe (A) Bleomycin 10 μg/ml or NaCl 0.9% with (red, circles) and without (blue, triangles) USMB at three pressures (MI 0.6, 0.5 and 0.4). Symbols indicate individual measurements and bars indicate mean and SD (n ≥ 3). *p < 0.05 **p < 0.01 (B) Flow cytometry analysis of Propidium Iodide and Annexin V staining 48 h after bleomycin 10 μg/ml or NaCl 0.9% with or without USMB at P_{neg} 0.59 MPa (MI 0.6), pie charts represent the mean of the samples with n = 2 or (for bleomycin + USMB samples) n = 3. (C) Representative dot plots of flow cytometry analysis shown in (B). More apoptosis and necrosis was observed after bleomycin + USMB. Bleo: bleomycin; MI: Mechanical Index; P_{neg}: Peak negative pressure; USMB: ultrasound and microbubbles.
are polydisperse. However, recent papers show that monodisperse microbubbles have a more uniform acoustic response and an increased imaging sensitivity (Segers et al., 2018; Helbert et al., 2020), which will also improve the reproducibility and controllability of USMB therapy.

We hypothesized that USMB therapy with a clinical US system and approved microbubbles could improve the local efficacy of chemotherapy. Both the Alamar Blue assay and the flow cytometry analysis showed that in vitro USMB therapy with both the clinical and the custom-built US system clearly increased the cytotoxicity of the hydrophilic drug bleomycin. However, our absolute IC₅₀ values have to be interpreted with caution. The nonlinear regression model included only one concentration above the IC₅₀ for the cells treated with USMB, and none for the cells treated without USMB. This led to a large confidence interval in the IC₅₀ estimations. Unfortunately, due to a worldwide shortage of bleomycin (Carrai, 2019) it was not feasible to increase the concentration further, in order to achieve an effect closer to 100% cell death. For this reason, we additionally calculated the IC₂₅ of each group and compared those. These data confirmed the increased cytotoxicity of bleomycin with the addition of USMB therapy.

While in clinical practice bleomycin is only used in a few tumor types, these results could be extended to a wide range of treatments with other hydrophilic chemotherapeutics. For example, based on previous in vitro results of Lammertink et al. future patients receiving chemotherapy or chemoradiation containing cisplatin could benefit from the addition of local USMB therapy (Lammertink et al., 2016). Furthermore, USMB therapy could be used to enhance the effect of therapeutic antibodies or nanoparticles (Heath et al., 2012; Togtema et al., 2012; Bellary et al., 2020; Snipstad et al., 2021a; Snipstad et al., 2021b). Finally, clinical studies evaluating the potential of USMB therapy in addition to radiotherapy in the absence of drugs are ongoing (Shi et al., 2021) (Clinicaltrials.gov NCT04431674, NCT04431648).

The custom-made TwentiCells used in our experiments are an attractive alternative to for example CLINICells and provide the opportunity to perform USMB experiments with a large number of independently sonicated samples, while using small volumes of medium, drugs and microbubbles. In addition, the TwentiCells hardly interfere with the applied ultrasound field, a common limitation of in vitro US set-ups (Hensel et al., 2011; Leskinen and Hynynen, 2012). To obtain reliable and reproducible results we standardized the procedures throughout our experiments as much as possible. This is essential, as many parameters [e.g., position of cells with respect to transducer, time between preparation and use of microbubbles, time between addition of microbubbles and sonication (Keller et al., 2019; Beekers et al., 2020)] can affect outcome of USMB therapy.

To conclude, we have shown that a non-modified clinical US system in combination with clinically approved microbubbles can be used to perform highly effective USMB therapy in vitro. The next step towards clinical translation is to apply these methods in vivo. Future trials should determine the safety and efficacy of our methods and US parameters in patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

JM, CB, CM, and RD conceived and designed the analysis. JM, CR, and RD collected the data. BE, HV, GL, and RD contributed data or analysis tools. JM, BE, and RD performed the analysis. JM and RD wrote the manuscript. CR, BE, HV, GL, CB, and CM revised and approved the submitted version.

FUNDING

We will apply for reimbursement of (part of) the publication fee from the Utrecht University Open Access Fund. The contribution of CR to this research was funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 722717.

ACKNOWLEDGMENTS

-The researchers and technicians of the department of Pharmaceutics, Utrecht University, for the opportunity to use their laboratory facilities and for their support.

-Kim van der Wurff-Jacobs for her assistance with the flow cytometry experiments.

-Corlinda ten Brink from Cell Microscopy Core, Department of Cell Biology, Center for Molecular Medicine, UMC Utrecht, for use of the LSM700 and technical support.

-Sandra Bruggink for her work on the bleomycin IC₅₀ experiments during her internship.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.768436/full#supplementary-material

REFERENCES

Beekers, I., Vegter, M., Lattwein, K. R., Mastik, F., Beurskens, R., van der Steen, A. F. W., et al. (2020). Opening of Endothelial Cell-Cell Contacts Due to Sonoporation. J. Control. Release 322, 426–438. doi:10.1016/j.jconrel.2020.03.038

Bellary, A., Villarreal, A., Eslami, R., Undseth, Q. J., Lec, B., Defnet, A. M., et al. (2020). Perfusion-guided Sonopermeation of Neuroblastoma: A Novel Strategy for Monitoring and Predicting Liposomal Doxorubicin Uptake In Vivo. Theranostics 10 (18), 8143–8161. doi:10.7150/thno.45903

Bing, K. F., Howles, G. P., Qi, Y., Palmeri, M. L., and Nightingale, K. R. (2009). Blood-brain Barrier (BBB) Disruption Using a Diagnostic Ultrasound System in Combination with Clinically Approved Microbubbles can be
Sonoporation. J. Oral Pathol. Med. 38 (7), 572–579. doi:10.1111/j.1600-0714.2009.00759.x

Miller, D. L., Dou, C., and Song, J. (2003). DNA Transfer and Cell Killing in Epidermoid Cells by Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies In Vitro. Ultrasound Med. Biol. 29 (4), 601–607. doi:10.1016/S0301-5629(02)00783-4

Miller, D. L., and Quddus, J. (2000). Sonoporation of Monolayer Cells by Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies. Ultrasound Med. Biol. 26, 661–667. doi:10.1016/S0301-5629(99)00170-2

Phillips, L. C., Klbanov, A. L., Warnhoff, B. R., and Hossack, J. A. (2010). Targeted Gene Transfection from Microbubbles into Vascular Smooth Muscle Cells Using Focused, Ultrasound-Mediated Delivery. Ultrasound Med. Biol. 36 (9), 1470–1480. doi:10.1016/j.ultrasmedbio.2010.06.010

Rahim, A., Taylor, S. L., Bush, N. L., ter Haar, G., Bamber, J. C., and Porter, C. D. (2010). Targeted Delivery of Cis-Diamminedichloroplatinum (II) to Cervical Cancer Cells: A Cytotoxic Anticancer Agent into the Metastatic Lymph Node Using Nano/microbubbles. J. Membr. Biol. 249 (5), 677–689. doi:10.1007/s00232-016-9911-4

Tang, M. X., and Eckersley, R. J. (2007). Frequency and Pressure Dependent Attenuation and Scattering by Microbubbles. Ultrasound Med. Biol. 33 (1), 164–168. doi:10.1016/j.ultrasmedbio.2006.07.031

ter Haar, G., Shaw, A., Pye, S., Ward, B., Bottomley, F., Nolan, R., et al. (2011). Guidance on Reporting Ultrasound Exposure Conditions for Bio-Effects Studies. Ultrasound Med. Biol. 37 (2), 177–183. doi:10.1016/j.ultrasmedbio.2010.10.021

Togtuma, M., Pichardo, S., Jackson, R., Lambert, P. F., Curtel, L., and Zehbe, I. (2012). Sonoporation Delivery of Monoclonal Antibodies against Human Papillomavirus 16 E6 Restores P53 Expression in Transformed Cervical Keratinocytes. PLoS One 7 (11), e00730. doi:10.1371/journal.pone.00730

Trédan, O., Galmarini, C. M., Patel, K., and Tannock, I. F. (2007). Drug Resistance and the Solid Tumor Microenvironment. J. Natl. Cancer Inst. 99 (19), 1441–1454. doi:10.1093/jnci/djm135

van der Meer, S. M., Versluis, M., Lohse, D., Chin, C. T., Bouakaz, A., and Jong, N. d. (2004). The Resonance Frequency of Sonovue as Observed by High-Speed Optical Imaging. IEEE Ultrason. Symp. 1, 343–345. doi:10.1109/ULTSYM.2004.1417735

van Ramshorst, M. S., van der Voort, A., van Werkhoven, E. D., Mandjes, I. A., Kemper, L., Dezentje, V. O., et al. (2018). Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): a Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 19 (12), 1630–1640. doi:10.1016/S1470-2045(18)33050-9

Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., et al. (2008). Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer. N. Engl. J. Med. 359 (11), 1116–1127. doi:10.1056/NEJMoa0802656

Versteijne, E., Sucker, M., Groothuis, K., Akkermans-Vogelaar, J. M., Besselink, M. G., Bonsing, B. A., et al. (2020). Preoperative Chemoradiotherapy versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J. Clin. Oncol. 38 (16), 1763–1773. doi:10.1200/JCO.2019.02274

Wang, Y., Li, Y., Yan, K., Shen, L., Yang, W., Gong, J., et al. (2018). Clinical Study of Ultrasound and Microbubbles for Enhancing Chemotherapeutic Sensitivity of Malignant Tumors in Digestive System. Chin. J. Cancer Res. 30 (5), 553–563. doi:10.21147/jcrr.9006.2018.05.09

Watanabe, Y., Aoi, A., Horie, S., Tomita, N., Mori, S., Morikawa, H., et al. (2008). Low-intensity Ultrasound and Microbubbles Enhance the Antitumor Effect of Cisplatin. Cancer Sci. 99 (12), 2525–2531. doi:10.1111/j.1349-7006.2008.00899.x

Zhou, Z., Wen, Y., Liao, D., Miao, J., Gui, Y., Cai, H., et al. (2020). Single-Agent versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial. Oncologist 25 (12), e1900–e1908. doi:10.1634/theoncologist.2020-0808

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 de Maar, Bouw, van Elburg, Vos, Lajoie-Bond, Moen and Deckers. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.